A Phase 1, Open-Label, Dose-Escalation Study of a CDK9 Inhibitor, PRT2527, in Adult Patients With Advanced Solid Tumors: An Updated Analysis

Manish R. Patel, Atrayee Basu-Mallick, Filemon Dela Cruz, Douglas Orr, Alex Spira, Guru P. Sonpavde, Pooja Ghatalia, Christine Lihou, Neelesh Sharma, Peggy Scherle, Jennifer Xavier, William Sun, Sri Sahasranaman, Jason T. Henry